The average price of heart stents is reduced by 93%, and the average price of artificial hip and knee joints is reduced by 82%
The six batches of centralized procurement of drugs have saved more than 260 billion yuan in total
The State Council Information Office held a regular policy briefing on February 11 to introduce the centralized procurement of drugs and high-value medical consumables.
Chen Jinfu, deputy director of the National Medical Insurance Administration, introduced that the state organized centralized drug procurement in six batches and purchased a total of 234 kinds of drugs.
According to the National Medical Insurance Administration, special procurement of insulin will be launched in 2021, expanding centralized procurement from chemical drugs to biological drugs for the first time.
The centralized procurement of high-value medical consumables focuses on cardiology and orthopedics, two areas that are most concerned by the masses.
The centralized procurement of cardiac stents has been running smoothly for a year, and the total number of selected stents has reached 1.69 million, which is nearly 1.6 times the annual agreement procurement volume.
Last year, the centralized procurement of artificial joints organized by the state was carried out for more complex orthopedic consumables, which further expanded the coverage of the reform.
Local governments also actively carry out centralized procurement of medicines and consumables as required.
At present, all provinces have carried out centralized procurement of medicines and consumables through provincial or inter-provincial alliances.
From the perspective of procurement varieties, chemical drugs, proprietary Chinese medicines, and biological drugs are involved in the three major drug sectors. The two varieties of coronary balloon and ophthalmic intraocular lens have achieved full coverage of provincial-level centralized procurement.
With the deepening of centralized procurement, the varieties of centralized procurement generally show the characteristics of "price reduction, quantity increase, and high quality".
Specifically:
The price has returned to a reasonable level, and the masses have benefited significantly.
The average price of the first six batches of medicines was reduced by 53%, the average price of heart stents was reduced by 93%, and the average price of artificial hip and knee joints was reduced by 82%, which effectively squeezed out the artificial high space.
By the end of 2021, the centralized procurement of drugs and high-value medical consumables organized by the state has saved a total of more than 260 billion yuan, playing an important role in maintaining the stability of the overall level of pharmaceutical prices.
According to the monitoring of the pharmaceutical price index carried out by the National Medical Insurance Administration, the price level of chemical drugs in 2019 and 2020 continued to decline year-on-year, with a drop of about 7%.
Purchasing data from the drug platform also shows that the total cost of drugs in public medical institutions across the country has been steadily increasing while the usage continues to increase.
The quality of drugs and consumables for clinical use has been improved, and the demand for clinical services has been fully released.
According to statistics, among the varieties of centralized procurement, the proportion of people using original research drugs and generic drugs that pass the consistency evaluation of quality and efficacy has increased from about 50% before centralized procurement to more than 90%.
Before the centralized procurement, about 1/3 of the clinically used cardiac stents were made of stainless steel. After the centralized procurement, more than 95% of the stents with better performance were used. The centralized procurement effectively promoted the market substitution of high-quality products.
Compared with before the centralized collection, the usage of the centralized collection varieties has increased, and more patients have benefited. For example, the dosage of entecavir, a hepatitis B drug, has increased by 78%, and that of imatinib, a leukemia drug, has increased by 35%, indicating that the clinical needs have been fully released. More patients are treated.
Promote the formation of a new pattern of industry development driven by fair competition, quality assurance and innovation.
Through open, transparent, fair and just competition, centralized procurement has gradually improved the market-led price formation mechanism in the pharmaceutical field, guided enterprises to strengthen quality and cost control, actively carry out product research and development and consistency evaluation, and promote high-quality development of the industry.
Promote the linkage of "three doctors".
Centralized procurement promotes the optimization of the income structure of medical institutions, and transforms the incentive mechanism by retaining a certain proportion of the saved medical insurance funds for medical institutions, and also creates conditions for the reform of medical service prices and the reform of the salary system of public medical institutions.
In the next step, the National Medical Insurance Bureau will normalize and institutionalize the centralized procurement of drugs and high-value medical consumables, making centralized procurement the basic mode of procurement for public medical institutions.
The centralized procurement of medicines is carried out in an all-round way in the three major sectors of chemical medicines, proprietary Chinese medicines and biological medicines.
By the end of 2022, the total number of national and provincial centralized procurement of medicines will reach more than 350 in each province, and the number of high-value medical consumables will reach more than 5, making centralized procurement the norm and stabilizing social expectations.
A reporter asked
When are dental implants included in the collection?
Regarding the specific arrangements for orthopedic consumables, dental implants and other consumables, Chen Jinfu, deputy director of the National Medical Security Administration, introduced that spinal consumables are undergoing thorough research and information standardization.
Because the clinical needs of orthopaedics are very large, but the standards are different, especially the composition of products is very complex, so how to form a procurement product group according to the needs of clinical medical care, which involves a high technical link, and is now researching the plan, and will soon be Carry out special research with the joint procurement of high-value medical consumables, and extensively listen to the opinions of clinical experts and enterprises, and strive to form a set of preliminary plans in the first half of the year. If the conditions are mature, the bid opening can be carried out smoothly this year.
Dental implants are an important treatment for missing teeth and are in great social demand.
Of course, there are many services provided by medical institutions.
Therefore, it has been deployed since the beginning of last year. Sichuan organized an inter-provincial alliance to study the procedures for the centralized procurement of dental implants. The reform of the alliance is also a centralized acquisition method explored in dental implants.
This group of articles / reporter Zhang Xin
Coordination / Yu Meiying